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Background: Berberine was encapsulated in yeast cells of Saccharomyces cerevisiae as novel carriers to be used in
different food and drug industries. The microcapsules were characterized by differential scanning calorimetry (DSC),
fourier transform infra red spectroscopy (FT-IR) and fluorescence microscopy. The encapsulation factors such as
plasmolysis of yeast cells which affects the % encapsulation yield were studied.
Results: Fluorescence microscopy showed the yeast cells became fluorescent after encapsulation process. DSC
diagram was representing of new peak for microcapsule which was not the same as berberine and the empty
yeast cells peaks, separately. FTIR spectrums of microcapsules and yeast cells were almost the same. The
plasmolysed and non plasmolysed microcapsules were loaded with berberine up to about 40.2 ± 0.2% w/w.
Conclusion: Analytical methods proved that berberine was encapsulated in the yeast cells. Fluorescence
microscopy and FTIR results showed the entrance of berberine inside the yeasts. DSC diagram indicated the
appearance of new peak which is due to the synthesis of new product. Although plasmolysis caused changes in
yeast cell structure and properties, it did not enhance berberine loading in the cells. The results confirmed that
Saccharomyces cerevisiae could be an efficient and safe carrier for active materials.
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Microencapsulation is a process that nowadays developed
in many industries. Encapsulation has a lot of advantages.
The encapsulated compound can be released in a con-
trolled way in different systems. Besides, it stabilizes the
active materials against oxygen or other molecules by wall
material as a physical barrier [1]. The stability and release
properties of microcapsules are dependent on cell wall
properties [2,3]. However, the new or novel coatings
are needed due to the cost and legal limits in the food
industries [4].
Saccharomyces cerevisiae yeast cell can be mentioned
as an ideal carrier due to its food-grade and low cost
characteristics. Unlike other carriers, it does not depend
on active ingredients for its synthesis. We could culture
this kind of carriers as much as needed without any excess
expenses. Besides, its membrane phospholipids act like
liposome structure and have been used for encapsulation* Correspondence: khashaiarmaneshz@mums.ac.ir
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reproduction in any medium, provided the orof different molecules, hydrophobic and hydrophilic, like
resveratrol [5-8].
It possesses the external thick cell wall which composes
of a beta glucan network and a small amount of chitin
associated with a mannoprotein layer [9]. These cell
wall properties make S. cerevisiae such a kind of sustained
release drug delivery system. The mechanical characteris-
tics of the yeasts structure allow them to load different
molecules.
Barberry (Berberis vulgaris L. family Berberidaceae)
grows in Asia and Europe. The plant is famous worldwide
for its medicinal properties [10]. Berberine is the most
significant alkaloid of this plant which is responsible for
its beneficial effects. Berberine is mostly accumulated in
the root. Berberine as an isoquinoline alkaloid is a
member of protoberberines class [11]. Berberine shows a
lot of pharmacological effects [12].
Berberine shows antiplatelet effects and it is also used
in treatment of congestive heart failure (CHF) [13-16].
Extracts are used to cure various inflammatory diseases
such as lumbago and rheumatism and to reduce fever
[17]. The reports represented immunosuppressive effecttd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 DSC thermograms of microcapsules, Saccharomyces cerevisiae yeast cell, berberine, plasmolysed yeast cells and physical
mixture of berberine and yeast cells.
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Peng et al. showed the antianxiety properties of berberine
[11]. Berberine can be mentioned as an expectorant due
to its ability to increase mucin release [18].
Berberine has been used to treat infectious diarrhea and
gastroenteritis in China in the past [19]. Berberine is defined
as an effective drug to cure acute diarrhea which is due to
Escherichia coli or Vibrio cholerae [20,21]. Berberine shows
significant antibacterial and antifungal activity against broad
spectrum of microorganisms [22-28].
Berberine’s poor water solubility and susceptibility to
environmental conditions prevent its application in many
industries. The goal of this study was to evaluate the new
aspect of yeast cells of S. cerevisiae as an encapsulation
carrier for berberine. Moreover, the berberine microcap-
sules were studied by different analytical methods such as
fluorescence microscopy, (DSC) and (FT-IR).
Methods
Preparation of plasmolysed yeast cells, non plasmolysed
yeast cells and berberine microcapsules
The yeast cells (commercially Bakers S. cerevisiae)
were cultured in soybean casein digest broth medium
(Himedia, India) for 10 hours [29] in shaker incubator
(20 rpm) (JTSL 20, Iran). The medium was centri-
fuged and the yeast cells were washed for three times
with deionised water. The final cells were classified in
two groups. First group as non plasmolysed cells was dir-
ectly freeze dried. The second one as plasmolysed cells
was plasmolysed in different concentration of sodium
chloride solutions. The yeast cells suspensions were pro-
vided in three different flasks. Each flask contained 10%,
20%, 30% w/w NaCl solutions, respectively. Then theflasks were stirred at 200 rpm for 72 h. The plasmolysed
cells were centrifuged and washed three times with deio-
nised water to remove impurities. At last, they have been
freeze-dried. The freeze-dried plasmolysed and non plas-
molysed yeast cells were studied as carriers [30].
Two kinds of freeze dried cells (plasmolysed and non
plasmolysed) (100 mg) were suspended in two flasks
containing 50 ml berberine solutions (500 mM). Berberine
hydrochloride was obtained from China (XI AN Rongsheng
biotechnology CO., LTD). The flasks were stirred at 200
rpm for 72 h and then centrifuged (6000 rpm, 20 min). The
precipitants were washed three times to remove the free
berberine. Then the berberine loaded microcapsules were
freeze dried.
Analytical methods for confirmation of berberine
encapsulation
Three methods were performed for confirmation of
encapsulation process including fluorescence micros-
copy (color CCTV camera, model No.MV-CP470/G),
fourier-transform Infrared Spectroscopy (FT-IR) (model.
Spectrum two) and differential scanning calorimetry (DSC)
(Mettler Toledo).
Fluorescence microscopy images were obtained from
empty freeze-dried yeast cells and the yeast cells which
encapsulated berberine. Besides Fluorescence microscopy,
DSC and FT-IR studies were carried out to confirm the
encapsulation of berberine in yeast cells.
In DSC studies, five types of freeze-dried samples were
studied: empty yeast cells, berberine powder,physical
mixture of berberine and empty cells, cells loaded with
berberine (microcapsules) and plasmolysed empty yeast
cells. To prepare a DSC sample, a definite amount of
Figure 2 FTIR spectra of Saccharomyces cerevisiae yeast cell and plasmolysed yeast cells.
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pans. The scan rate was 10°C/min between 0 and 400°C.
The IR spectra (KBr disc method) of all the above
mentioned samples were also obtained using an FT-IR
spectrophotometer [8,10].
To determine the encapsulation yield (% EY), berberine
was extracted from two kinds of microcapsules. In
extraction process, each sample ( 50 mg ) was suspended
in deionised water and ethanol by ratio of 1:4. Then the
suspensions were stirred for 48 h in room temperature.
Each cell suspension was then centrifuged. Berberine in the
supernatant was then quantified by UV/Visible spectros-
copy. Then the (% EY) was calculated [28]:
%EYð Þ ¼ Mass of encapsulated berberine
 Mass of the resulted microcapsule 100Results and discussion
Analytical studies of freeze-dried plasmolysed and non
plasmolysed yeast cells
The DSC thermograms are showed in Figure 1. DSC
thermograms indicate the heat capacity changes of a
product based on temperature or time. Besides, we can
prove the formation of a new product by omitting or
obtaining of new peaks. The DSC thermogram shows an
exothermic peak with maximum occurrence at 352°C for
freeze-dried non plasmolysed yeast (Figure 1). This peak is
originated from the phase transition temperature (Tm) of
yeasts’ phospholipid bilayer and at 352°C the hydrocarbon
tail melted [30]. Tm is influenced by membrane structure
so the DSC thermogram of the freeze-dried yeasts cells
that had been plasmolysed in 20% w/w NaCl solution
showed exothermic peaks with maximum occurrence at
284 and 340°C. It confirms that plasmolysis process causes
Figure 3 FTIR spectra of 10%, 20% and 30% plasmolysed Saccharomyces cerevisiae yeast cells.
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different maximum occurrence in comparison with non
plasmolysed yeast cells [31]. Tm also depends on different
parameters such as strain of S. cerevisiae, so we observed
different Tm in different studies.
FT-IR was also used to study changes in the cells
structure as a result of yeast cell plasmolysis. The IR
spectra of both plasmolysed and non plasmolysed freeze-
dried yeast cells are shown in Figure 2. The spectra of dif-
ferent plasmolysed yeast cells with 10%, 20% and 30% w/w
NaCl solutions (Figure 3) show no significant differences
among each other but in comparison with the spectra
of non plasmolysed yeast cells (Figure 2), we could see
characteristic changes that they represent the effects of
plasmolysis on cell wall or membrane compositions
such as proteins, carbohydrates, lipids and even nu-
cleic acids.
The contributions of hydroxyl vibrations of carbohydrates
and NH vibrations of proteins can be observed in a band at
3750–3000 cm-1 in IR spectra [31].
Region 3050–2700 cm-1 shows us the information about
lipid composition of yeast cells. Plasmolysed yeast cells
indicated a minor increase of their absorption intensities
due to the changes in the length of membrane lipid chains
in comparison with non plasmolysed yeast cells absorption
peaks in 2959 and 2925 cm-1 (Figure 2) [32]. These two
peaks are due to the vibrations of methyl and methylene
groups. Plasmolysis effects on cell wall and membrane
proteins could be seen in different regions. According to
protein degradation by plasmolysis, we faced some changes
in peak intensities in the region 1700–1550 cm-1. After
plasmolysis, some changes happened in the absorption
bands at 1659 and 1553 cm-1, which referred to protein
amide I and amide II and carbon-nitrogen vibrations of
yeast cells due to the shift of the degradated proteins to an
unfolded state. Degradation of one part of yeast proteins in
the cell membrane and the cell wall could be detected
in the band region from 1530 to 1385 cm-1.(a)
Figure 4 Fluorescence micrographs of berberine yeast microcapsulesPlasmolysis caused the cell wall polysaccharides deg-
radation which could be detected by changes in the IR
region from 1156 to 768 cm-1 (Figure 2).
Hypophosphite vibrations are originated from nucleic
acid molecules, so we could find the effect of plasmolysis
on nucleic acids degradation as the 1240 cm-1. Nucleic
acid molecules are placed inside the cell so the presence
of their IR spectra are indicative of cells which are not
completely emptied by plasmolysis (Figure 2).
Finally the results show us that plasmolysis causes
disorganisation to the cell plasma membrane and thickness
of cell wall but higher concentrations of NaCl solutions
showed no additional disruptions in the yeast cell.
Plasmolysis enhances the intracellular space so it im-
proves the capacity of carriers for encapsulation process
[33]. Nowadays, yeast cells plasmolysis with NaCl [7]
were mainly used for the encapsulation of different ac-
tive materials.
The results indicated that the %encapsulation yield
values were statistically similar (p > 0.05) amongst plas-
molysed and non plasmolysed cells which confirms other
researches results [30]. The average %encapsulation yield
was 40.2±0.2%. No differences were observed in the
%encapsulation yield amongst plasmolysed yeast cells
when exposed to 10%, 20% or 30% w/w NaCl.
Analytical studies for confirmation of berberine
encapsulation
In the fluorescence micrographs, empty yeast cells could
not emit fluorescence (Figure 4b). But the yeast cells
loaded with berberine emitted fluorescence due to the
presence of berberine which shows fluorescence properties
(Figure 4a). This event proved the interaction of berberine
with yeast cells. Further analyses were carried out using
DSC and FT-IR to find out the effect of plasmolysis on
cells structure.
Figure 1 showed the DSC thermograms of non-plasmolysed
yeast cells, berberine, physical mixture of berberine and(b)
(a) and empty Saccharomyces cerevisiae yeast cells (b).
Figure 5 FTIR spectra of Saccharomyces cerevisiae yeast cells, berberine, berberine microcapsules and physical mixture.
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lysed yeast cells.
The new peak that appeared at 289°C which differed
from the peak of empty yeast cells and physical mixture
showed that the new product was produced. This Tm
variation was due to decrease of Van der Waals interactions
happened to membrane as a result of berberine’s integra-
tion. On the other hand, berberine influenced the bilayer
organization by interaction of its polar groups with
membrane polar groups. So the membrane became
more fluid and Tm of microcapsules was lowered in
comparison with empty yeast cells.
The samples were studied with FTIR spectroscopy too
and their spectra are showed in Figure 5. The interaction
of berberine with yeast cell would alter the intensity
of yeast cell absorption bands and causes shifts of
characteristic bands.
The characteristic absorption bands of berberine are
shown in Figure 5. The IR spectra of empty yeast cells are
explained before. The 3298 and 1654 cm-1 bands are due
to the phenolic and carbonyl groups, respectively. The
absorption peak at 1545 cm-1 shows us the carbonyl and
carbon-carbon vibration. The peak at 1451 cm-1 refered
to carbon-hydrogen vibration. The absorption peak at
1238 cm-1 is indicative of phenolic vibration. The methoxy
groups are responsible for the 1080 cm-1 band. The aro-
matic carbon-hydrogen group vibrates at 914 cm-1 [34].
The IR spectrum of the physical mixture of berberine and
yeast cells was a combination of the IR spectra of empty
yeast cells and berberine, separately. The IR spectra of the
microcapsules was relatively the same as the spectrum of
the empty yeast cells. These spectra could prove the fact
that berberine was placed inside the yeast cells. This obser-
vation confirmed Shi et al. [5,7] studies. However we had
some peak disappearances at 914 cm-1 and variation in the
absorption bands of 1654 and 1545 cm-1 as a result of
berberine-protein interactions in microcapsules spectra.
Conclusions
In this study, S. cerevisiae were introduced as a novel
carrier for berberine as a model. It has shown that
yeast microcapsules were loaded with berberine up to
40.2 ± 0.2% w/w. Three analytic methods indicated that
berberine located inside the cells mainly by hydrophobic
interactions with the yeast cell membrane and cell wall.
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